Liminal BioSciences, Inc.
(NASDAQ : LMNL)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.47%131.020.0%$2314.17m
BNGOBioNano Genomics, Inc. 18.50%9.800.0%$2016.46m
GILDGilead Sciences, Inc. -0.06%66.941.0%$649.72m
AMGNAmgen, Inc. 0.58%253.501.3%$564.60m
CRSPCRISPR Therapeutics AG 1.83%188.490.6%$487.99m
REGNRegeneron Pharmaceuticals, Inc. 0.43%537.782.7%$478.09m
ALXNAlexion Pharmaceuticals, Inc. 1.19%159.732.0%$470.59m
NVAXNovavax, Inc. 3.74%126.9892.9%$417.43m
ILMNIllumina, Inc. 0.34%406.253.5%$396.72m
SRPTSarepta Therapeutics, Inc. 1.36%98.2413.8%$364.79m
VRTXVertex Pharmaceuticals, Inc. -0.44%237.591.9%$361.85m
BIIBBiogen, Inc. -0.25%269.441.7%$321.90m
BNTXBioNTech SE 2.86%108.440.0%$298.33m
EXASEXACT Sciences Corp. 1.30%150.0019.6%$243.95m
PACBPacific Biosciences of California, Inc. 3.06%37.427.4%$228.17m

Company Profile

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.